These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15788051)

  • 1. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients.
    Reilly JP; Grise MA; Fortuin FD; Vale PR; Schaer GL; Lopez J; VAN Camp JR; Henry T; Richenbacher WE; Losordo DW; Schatz RA; Isner JM
    J Interv Cardiol; 2005 Feb; 18(1):27-31. PubMed ID: 15788051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.
    Sarkar N; Rück A; Källner G; Y-Hassan S; Blomberg P; Islam KB; van der Linden J; Lindblom D; Nygren AT; Lind B; Brodin LA; Drvota V; Sylvén C
    J Intern Med; 2001 Nov; 250(5):373-81. PubMed ID: 11887971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations.
    Povsic TJ; Henry TD; Ohman EM; Pepine CJ; Crystal RG; Rosengart TK; Reinhardt RR; Dittrich HC; Traverse JH; Answini GA; Mokadam NA
    Am Heart J; 2021 Nov; 241():38-49. PubMed ID: 34224684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-D
    Leikas AJ; Hassinen I; Hedman A; Kivelä A; Ylä-Herttuala S; Hartikainen JEK
    Gene Ther; 2022 May; 29(5):289-293. PubMed ID: 34593990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris.
    Sylvén C; Sarkar N; Rück A; Drvota V; Hassan SY; Lind B; Nygren A; Källner Q; Blomberg P; van der Linden J; Lindblom D; Brodin LA; Islam KB
    Coron Artery Dis; 2001 May; 12(3):239-43. PubMed ID: 11352080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.
    Kastrup J; Jørgensen E; Rück A; Tägil K; Glogar D; Ruzyllo W; Bøtker HE; Dudek D; Drvota V; Hesse B; Thuesen L; Blomberg P; Gyöngyösi M; Sylvén C;
    J Am Coll Cardiol; 2005 Apr; 45(7):982-8. PubMed ID: 15808751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up.
    Haack-Sørensen M; Friis T; Mathiasen AB; Jørgensen E; Hansen L; Dickmeiss E; Ekblond A; Kastrup J
    Cell Transplant; 2013; 22(3):521-8. PubMed ID: 22472086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia.
    Losordo DW; Vale PR; Hendel RC; Milliken CE; Fortuin FD; Cummings N; Schatz RA; Asahara T; Isner JM; Kuntz RE
    Circulation; 2002 Apr; 105(17):2012-8. PubMed ID: 11980678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF gene therapy for angiogenesis in refractory angina: phase I/II clinical trial.
    Kalil RA; Salles FB; Giusti II; Rodrigues CG; Han SW; Sant'Anna RT; Ludwig E; Grossman G; Prates PR; Sant'anna JR; Teixeira Filho GF; Nardi NB; Nesralla IA
    Rev Bras Cir Cardiovasc; 2010; 25(3):311-21. PubMed ID: 21103738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.
    Losordo DW; Schatz RA; White CJ; Udelson JE; Veereshwarayya V; Durgin M; Poh KK; Weinstein R; Kearney M; Chaudhry M; Burg A; Eaton L; Heyd L; Thorne T; Shturman L; Hoffmeister P; Story K; Zak V; Dowling D; Traverse JH; Olson RE; Flanagan J; Sodano D; Murayama T; Kawamoto A; Kusano KF; Wollins J; Welt F; Shah P; Soukas P; Asahara T; Henry TD
    Circulation; 2007 Jun; 115(25):3165-72. PubMed ID: 17562958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina--final 3-year follow-up.
    Mathiasen AB; Haack-Sørensen M; Jørgensen E; Kastrup J
    Int J Cardiol; 2013 Dec; 170(2):246-51. PubMed ID: 24211066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial.
    Favaloro L; Diez M; Mendiz O; Janavel GV; Valdivieso L; Ratto R; Garelli G; Salmo F; Criscuolo M; Bercovich A; Crottogini A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):899-906. PubMed ID: 22777825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraoperative multiplane transesophageal echocardiography for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris.
    Esakof DD; Maysky M; Losordo DW; Vale PR; Lathi K; Pastore JO; Symes JF; Isner JM
    Hum Gene Ther; 1999 Sep; 10(14):2307-14. PubMed ID: 10515450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catheter-based percutaneous myocardial laser revascularization in patients with end-stage coronary artery disease.
    Lauer B; Junghans U; Stahl F; Kluge R; Oesterle SN; Schuler G
    J Am Coll Cardiol; 1999 Nov; 34(6):1663-70. PubMed ID: 10577553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.
    Lathi KG; Vale PR; Losordo DW; Cespedes RM; Symes JF; Esakof DD; Maysky M; Isner JM
    Anesth Analg; 2001 Jan; 92(1):19-25. PubMed ID: 11133594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.
    Stewart DJ; Hilton JD; Arnold JM; Gregoire J; Rivard A; Archer SL; Charbonneau F; Cohen E; Curtis M; Buller CE; Mendelsohn FO; Dib N; Page P; Ducas J; Plante S; Sullivan J; Macko J; Rasmussen C; Kessler PD; Rasmussen HS
    Gene Ther; 2006 Nov; 13(21):1503-11. PubMed ID: 16791287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of percutaneous intramyocardial bone marrow cell injection for chronic myocardial ischemia: Long-term results.
    Rodrigo SF; Mann I; van Ramshorst J; Beeres SL; Zwaginga JJ; Fibbe WE; Bax JJ; Schalij MJ; Atsma DE
    J Interv Cardiol; 2017 Oct; 30(5):440-447. PubMed ID: 28752630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracoronary autologous CD34+ stem cell therapy for intractable angina.
    Wang S; Cui J; Peng W; Lu M
    Cardiology; 2010; 117(2):140-7. PubMed ID: 20975266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
    Symes JF; Losordo DW; Vale PR; Lathi KG; Esakof DD; Mayskiy M; Isner JM
    Ann Thorac Surg; 1999 Sep; 68(3):830-6; discussion 836-7. PubMed ID: 10509970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for ischemic heart disease: therapeutic potential.
    Symes JF
    Am J Cardiovasc Drugs; 2001; 1(3):159-66. PubMed ID: 14728030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.